NYSE: NEUE
Neuehealth Inc Stock Forecast, Predictions & Price Target

Analyst price target for NEUE

Based on 1 analyst offering 12 month price targets for Neuehealth Inc

Min Forecast
$7.00-4.66%
Avg Forecast
$7.00-4.66%
Max Forecast
$7.00-4.66%

Should I buy or sell NEUE stock?

Based on 1 analyst offering ratings for Neuehealth Inc.

Hold
Strong Buy
0 analysts 0%
Buy
0 analysts 0%
Hold
1 analysts 100%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their NEUE stock forecasts and price targets.

NEUE stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-12-09

1 of 1

Forecast return on equity

Is NEUE forecast to generate an efficient return?

Insufficient data to display

Forecast return on assets

Is NEUE forecast to generate an efficient return on assets?

Company
-10.71%
Industry
7.33%
NEUE is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

NEUE earnings per share forecast

What is NEUE's earnings per share in the next 1 years based on estimates from 1 analyst?

Avg 1 year Forecast
-$9.01

NEUE revenue forecast

What is NEUE's revenue in the next 1 years based on estimates from 1 analyst?

Avg 1 year Forecast
$1.1B+6.82%

NEUE vs Healthcare Plan Stocks

TickerPricePrice TargetUp/downsideConsensus
NEUE$7.34$7.00-4.66%Hold
CLOV$4.54$5.00+10.13%Buy
ALHC$13.87$12.83-7.48%Buy
OSCR$13.06$19.13+46.44%Hold
MOH$270.67$351.00+29.68%Buy

Neuehealth Stock Forecast FAQ

Is Neuehealth Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NYSE: NEUE) stock is to Hold NEUE stock.

Out of 1 analyst, 0 (0%) are recommending NEUE as a Strong Buy, 0 (0%) are recommending NEUE as a Buy, 1 (100%) are recommending NEUE as a Hold, 0 (0%) are recommending NEUE as a Sell, and 0 (0%) are recommending NEUE as a Strong Sell.

If you're new to stock investing, here's how to buy Neuehealth stock.

What is NEUE's earnings growth forecast for 2025-2025?

(NYSE: NEUE) Neuehealth's forecast annual earnings growth rate of N/A is not forecast to beat the US Healthcare Plans industry's average forecast earnings growth rate of N/A, and while it is not forecast to beat the US market's average forecast earnings growth rate of N/A.

Neuehealth's earnings in 2025 is -$412,715,000.

In 2025, NEUE is forecast to generate -$74,645,940 in earnings, with the lowest earnings forecast at -$74,645,940 and the highest earnings forecast at -$74,645,940.

What is NEUE's revenue growth forecast for 2025-2025?

(NYSE: NEUE) Neuehealth's forecast annual revenue growth rate of N/A is not forecast to beat the US Healthcare Plans industry's average forecast revenue growth rate of N/A, and while it is not forecast to beat the US market's average forecast revenue growth rate of N/A.

Neuehealth's revenue in 2025 is $996,890,000.

In 2025, NEUE is forecast to generate $8,822,222,198 in revenue, with the lowest revenue forecast at $8,822,222,198 and the highest revenue forecast at $8,822,222,198.

What is NEUE's forecast return on assets (ROA) for 2025-2025?

(NYSE: NEUE) forecast ROA is -10.71%, which is lower than the forecast US Healthcare Plans industry average of 7.33%.

What is NEUE's Price Target?

According to 1 Wall Street analyst that have issued a 1 year NEUE price target, the average NEUE price target is $7.00, with the highest NEUE stock price forecast at $7.00 and the lowest NEUE stock price forecast at $7.00.

The Wall Street analyst predicted that Neuehealth's share price could fall to $7.00 by Dec 9, 2025. The average Neuehealth stock price prediction forecasts a potential downside of 4.66% from the current NEUE share price of $7.34.

What is NEUE's Earnings Per Share (EPS) forecast for 2025-2025?

(NYSE: NEUE) Neuehealth's current Earnings Per Share (EPS) is -$51.02. In 2025, NEUE's EPS is forecast to hit -$9.01 (min: -$9.01, max: -$9.01).

What is NEUE's forecast return on equity (ROE) for 2025-2025?

(NYSE: NEUE) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.